Hillstream Biopharma (NASDAQ:CNTN) Trading 7.3% Higher – What’s Next?

Shares of Hillstream Biopharma Inc. (NASDAQ:CNTN) traded up 7.3% during trading on Wednesday . The stock traded as high as $3.64 and last traded at $3.54. 1,382,389 shares changed hands during trading, an increase of 53% from the average session volume of 903,791 shares. The stock had previously closed at $3.30.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings raised shares of Hillstream Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 3rd. Wall Street Zen raised shares of Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Hillstream Biopharma Stock Performance

The stock has a market cap of $247.13 million, a PE ratio of -3.08 and a beta of 1.41. The company has a fifty day moving average of $3.19.

Hillstream Biopharma (NASDAQ:CNTN) last issued its earnings results on Tuesday, March 31st. The company reported $0.54 earnings per share (EPS) for the quarter.

Insider Activity

In other news, Director Gary S. Stetz sold 87,851 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $3.42, for a total value of $300,450.42. Following the transaction, the director owned 146,675 shares in the company, valued at approximately $501,628.50. This trade represents a 37.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company’s stock.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.